Guardant Health (Guardant Health) COGS-to-Revenue : 0.39 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Guardant Health COGS-to-Revenue?

Guardant Health's Cost of Goods Sold for the three months ended in Mar. 2024 was $65.3 Mil. Its Revenue for the three months ended in Mar. 2024 was $168.5 Mil.

Guardant Health's COGS to Revenue for the three months ended in Mar. 2024 was 0.39.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Guardant Health's Gross Margin % for the three months ended in Mar. 2024 was 61.25%.

Guardant Health COGS-to-Revenue Historical Data

The historical data trend for Guardant Health's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guardant Health COGS-to-Revenue Chart

Guardant Health Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.33

0.32

0.33

0.35

0.40

Guardant Health Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															0.41	0.39	0.40	0.40	0.39

Guardant Health COGS-to-Revenue Calculation

Guardant Health's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	227.052	/	563.948
	=	0.40

Guardant Health's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	65.296	/	168.491
	=	0.39

Guardant Health (NAS:GH) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Guardant Health's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	65.296 / 168.491
	=	61.25 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Guardant Health COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Guardant Health's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Guardant Health (Guardant Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Guardant Health Inc (NAS:GH) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

5GH:Germany

Address

3100 Hanover Street, Palo Alto, CA, USA, 94304

Website

https://www.guardanthealth.com

Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Executives

Meghan V. Joyce	director	THE BOSTON BEER COMPANY, INC., ONE DESIGN CENTER PL., STE. 850, BOSTON MA 02210
Kumud Kalia	officer: Chief Information Officer	505 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Ines Dahne-steuber	officer: Chief Operating Officer	3100 HANOVER STREET, PALO ALTO CA 94304
Darya Chudova	officer: Chief Technology Officer	3100 HANOVER STREET, PALO ALTO CA 94304
Helmy Eltoukhy	director, officer: Chief Executive Officer	2 BARRY LANE, ATHERTON CA 94027
Amirali Talasaz	director, officer: Chairman, President and COO	18 ISABELLA AVENUE, ATHERTON CA 94027
Musa Tariq	director	3100 HANOVER STREET, PALO ALTO CA 94304
Amelia Merrill	officer: SVP, People	505 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Steve E. Krognes	director	863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Stanley J Meresman	director	2071 HUNTINGTON LANE, LOS ALTOS CA 94024
Myrtle S Potter	director	10 FINDERNE AVE, BRIDGEWATER NJ 08807
Ian T Clark	director	SOLAZYME, INC., 225 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Chris Freeman	officer: Chief Commercial Officer	505 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Bahija Jallal	director	120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Vijaya Gadde	director	C/O TWITTER INC, 1355 MARKET STREET SUITE 900, SAN FRANCISCO CA 94103